13.30

0.08% -0.010

Pre-market: 13.30

Amneal Pharmaceuticals Inc (AMRX)

Overview News Price History Option Chain Discussions Forecast

Amneal Pharmaceuticals Inc stock is traded at $13.30, with a volume of 2.25M. It is down -0.08% in the last 24 hours and down -7.83% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Previous Close:

$13.31

Open:

$13.42

24h Volume:

2.25M

Relative Volume:

0.95

Market Cap:

$4.18B

Revenue:

$3.02B

Net Income/Loss:

$127.93M

P/E Ratio:

60.10

EPS:

0.2213

Net Cash Flow:

$225.64M

1W Performance:

-8.78%

1M Performance:

-7.83%

6M Performance:

+39.27%

1Y Performance:

+50.45%

1-Day Range:

$13.20

$13.47

1-Week Range:

$13.08

$14.66

52-Week Range:

$6.685

$15.42

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name

Amneal Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (82)

Phone

908-947-3120

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater

Employee

5,210

Twitter

@amnealpharma

Next Earnings Date

2026-02-27

Latest SEC Filings

AMRX's Discussions on Twitter

Compare AMRX vs TAK, ZTS, HLN, TEVA, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMRX Amneal Pharmaceuticals Inc	13.30	4.18B	3.02B	127.93M	225.64M	0.2213
TAK Takeda Pharmaceutical Co Adr	18.22	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.96	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.47	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.91	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	490.21	21.85B	3.13B	1.27B	1.12B	26.39

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Jun-06-25	Initiated	Goldman	Buy
Feb-24-25	Upgrade	JP Morgan	Neutral → Overweight
Sep-06-24	Upgrade	JP Morgan	Underweight → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Mar-08-21	Upgrade	Goldman	Sell → Buy
Dec-14-20	Upgrade	Barclays	Equal Weight → Overweight
Dec-14-20	Upgrade	Guggenheim	Neutral → Buy
Jul-27-20	Initiated	Goldman	Sell
May-12-20	Upgrade	Guggenheim	Sell → Neutral
Dec-12-19	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-12-19	Downgrade	JP Morgan	Neutral → Underweight
Nov-07-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-11-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-08-19	Upgrade	Piper Jaffray	Neutral → Overweight
Jun-11-19	Initiated	Barclays	Equal Weight
May-21-19	Upgrade	Raymond James	Mkt Perform → Strong Buy
Mar-20-19	Initiated	SunTrust	Buy
Mar-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Dec-14-18	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-16-18	Downgrade	SunTrust	Buy → Hold
Aug-13-18	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jul-23-18	Initiated	Morgan Stanley	Overweight
Jun-22-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

Mar 03, 2026

Amneal (NYSE: AMRX) grants RSU and performance stock awards to EVP - Stock Titan

Mar 03, 2026

Amneal (NYSE: AMRX) EVP Andrew Boyer granted time- and performance-based RSUs - Stock Titan

Mar 03, 2026

AMRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026